FBR Capital analyst Christopher James lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) to $9.00 (from $30.00) following the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE